Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer breathes easy with Exubera data

Executive Summary

Type 1 and type 2 diabetes patients do not experience greater reductions in lung function with long-term use of Pfizer's inhaled insulin Exubera, the firm says. Data from an eight-year extension study of 217 adults from the three Phase III Exubera trials show the average yearly reductions in lung function were similar between treatment and control groups, Pfizer says. Lung function tests are advised in product labeling for initiation of therapy and regular monitoring for the inhaled product (1"The Pink Sheet" Feb. 13, 2006, p. 23). The study, presented at the European Association for the Study of Diabetes Sept. 18, also shows that blood sugar levels were maintained with long-term Exubera use. Pfizer also presents data from an eight-day study comparing Exubera to Sanofi-Aventis' long-acting insulin Lantus in uncontrolled type 2 diabetics. The 40-patient study shows "no differences in the blood sugar variability endpoints between Exubera and Lantus," Pfizer says, adding that additional large-scale studies comparing the insulins are ongoing...

You may also be interested in...



Exubera Education, Complicated Manufacturing Impacting Launch Timeline

Pfizer's mid-year launch timeline for its inhaled insulin therapy Exubera is influenced by the need to educate physicians, complex supply chain issues and reimbursement discussions, Pfizer co-development partner Nektar suggested

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel